BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($0.32), $0.19 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.